Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clare Scott

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
The Australian & New Zealand Journal of Obstetrics & Gynaecology|February 1, 2024
Mucinous ovarian carcinoma: A survey of practice in Australia and New ZealandNiveditha Rajadevan, Ariane Flinkier, Hugo Saunders, et al.
Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialM William Audeh, James Carmichael, Richard T Penson, et al.
British Journal of Cancer|November 9, 2016
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancerJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2011
Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancerSusan M Domchek, Gillian Mitchell, Geoffrey J Lindeman, et al.
The Lancet. Oncology|September 13, 2016
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trialJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Journal of Gynecologic Oncology|December 22, 2024
Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80)Jung-Yun Lee, David Tan, Isabelle Ray-Coquard, et al.
Cells|March 1, 2019
Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open QuestionsMarina Bagnoli, Ting Yan Shi, Charlie Gourley, et al.
British Journal of Cancer|October 25, 2018
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapyMichael Friedlander, Ursula Matulonis, Charlie Gourley, et al.
The Lancet. Oncology|July 21, 2018
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trialMichael Friedlander, Val Gebski, Emma Gibbs, et al.
Journal of the National Cancer Institute|February 7, 2002
Dominant negative ATM mutations in breast cancer familiesGeorgia Chenevix-Trench, Amanda B Spurdle, Magtouf Gatei, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
The Australian & New Zealand Journal of Obstetrics & Gynaecology|February 1, 2024
Mucinous ovarian carcinoma: A survey of practice in Australia and New ZealandNiveditha Rajadevan, Ariane Flinkier, Hugo Saunders, et al.
Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialM William Audeh, James Carmichael, Richard T Penson, et al.
British Journal of Cancer|November 9, 2016
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancerJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2011
Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancerSusan M Domchek, Gillian Mitchell, Geoffrey J Lindeman, et al.
The Lancet. Oncology|September 13, 2016
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trialJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Journal of Gynecologic Oncology|December 22, 2024
Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80)Jung-Yun Lee, David Tan, Isabelle Ray-Coquard, et al.
Cells|March 1, 2019
Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open QuestionsMarina Bagnoli, Ting Yan Shi, Charlie Gourley, et al.
British Journal of Cancer|October 25, 2018
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapyMichael Friedlander, Ursula Matulonis, Charlie Gourley, et al.
The Lancet. Oncology|July 21, 2018
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trialMichael Friedlander, Val Gebski, Emma Gibbs, et al.
Journal of the National Cancer Institute|February 7, 2002
Dominant negative ATM mutations in breast cancer familiesGeorgia Chenevix-Trench, Amanda B Spurdle, Magtouf Gatei, et al.
Pageof 6